Healthcare ❯ Pharmaceuticals ❯ Drug Development ❯ Weight Loss Drugs
Lilly’s stronger-than-expected Q2 with raised guidance highlights widening commercial momentum while Novo struggles to reassure investors as pipeline setbacks and guidance cool market confidence.
